Highlights
- •Satisfactory glycemic control is obtained by CSII treatment.
- •β-cell function and GLP-1 concentration improve significantly after treatment.
- •Overweight and middle-aged patient may get more benefit from the treatment.
Abstract
Objective
Early short-term intensive insulin therapy in newly diagnosed type 2 diabetes patients
shows benefit in glycemic control and β-cell function. Glucagon-like peptide-1 (GLP-1)
plays an important role in glucose metabolism and development of type 2 diabetes.
We did a study to observe the changes of GLP-1 and β-cell function after short-term
continuous subcutaneous insulin infusion (CSII) treatment.
Methods
A total of 66 subjects were enrolled, including 30 normal glucose tolerance controls
(NGT) and 36 patients with newly diagnosed type 2 diabetes between October 2015 and
July 2016. Fasting plasma glucose (FPG), insulin, and GLP-1 were measured in each
subject. The patients underwent CSII treatment for 2 weeks, and then FBG, insulin,
and GLP-1 were measured. HOMA-IR and HOMA-B were then calculated.
Results
All patients achieved target glycemic control in two weeks. HOMA-IR and HOMA-B improved
significantly after intensive interventions (p < 0.05). The GLP-1 concentration increased
significantly in patients after treatment (p < 0.05). When grouped according to bodyweight
and age in all patients, the HOMA-IR changed significantly in overweight and old age
subgroups, the HOMA-B increased significantly in normal weight, overweight and middle
age subgroups, and the GLP-1 concentration also increased significantly in overweight
and middle age subgroups respectively (p < 0.05).
Conclusion
Short-term CSII treatment can obtain glycemic control target and recover β-cell function
and GLP-1 secretion in newly diagnosed type 2 diabetes patients. The overweight and
middle-aged patients may get more benefit from this treatment.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Diabetes Research and Clinical PracticeAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.Diabetes Res Clin Pract. 2011; 94: 311-321
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–53.
- Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.Diabetes Care. 1997; 20: 1353-1356
- Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis.Lancet Diabetes Endocrinol. 2013; 1: 28-34
Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care, 2016;39 (Suppl. 1):S4-5.
Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18(3):361–76.
- Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study.J Comp Neurol. 1988; 271: 519-532
- The biology of incretin hormones.Cell Metab. 2006; 3: 153-165
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).Lancet. 2009; 374: 39-47
- Human blood pressure determination by sphygmomanometry.Circulation. 1993; 88: 2460-2470
- Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults.Biomed Environ Sci. 2002; 15: 83-96
World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999:17(2);151–83.
Stone NJ et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889–934.
- Correct homeostasis model assessment (HOMA) evaluation uses the computer program.Diabetes Care. 1998; 21: 2191-2192
- Beta-cell failure in diabetes and preservation by clinical treatment.Endocr Rev. 2007; 28: 187-218
- Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.Lancet. 2008; 371: 1753-1760
- Assessment of pancreatic beta-cell function: review of methods and clinical applications.Curr Diabetes Rev. 2014; 10: 2-42
- Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.Diabetes. 2010; 59: 1330-1337
- Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance.Int J Med Sci. 2012; 9: 574-581
- Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.J Clin Endocrinol Metab. 2001; 86: 3717-3723
- GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the aDDITION-PRO study.Diabetes. 2015; 64: 2513-2525
- Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.Diabetologia. 2013; 56: 965-972
- Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men.BMJ. 1995; 310: 560-564
- Impaired incretin secretion and pancreatic dysfunction with older age and diabetes.Metabolism. 2014; 63: 922-929
- Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.JAMA. 2004; 291: 335-342
- Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?.JAMA. 1990; 263: 2893-2898
Article info
Publication history
Published online: February 03, 2018
Accepted:
January 30,
2018
Received in revised form:
January 13,
2018
Received:
July 2,
2017
Identification
Copyright
© 2018 Elsevier B.V. All rights reserved.
